ONC: Malnutrition Screening and Nutrition Assessment of Adult Oncology Patients (2012)
Kwang AY, Kandiah M. Objective and subjective nutritional assessment of patients with cancer in palliative care. Am J Hosp Palliat Care. 2010 Mar; 27 (2): 117-126. Epub 2009 Dec 3.
PubMed ID: 19959839- The objective is to evaluate the nutritional status of patients with cancer in palliative care using objective and subjective nutritional assessments
- To determine potential inter-relationships between the methods.
All consecutive, mentally alert and ambulatory patients with cancer admitted as inpatients and outpatients at a palliative care unit of a Malaysian government hospital and a non-governmental hospice facility between January and April 2005.
- Non-ambulatory patients who had severe edema or ascites, were on enteral or parenteral nutrition support, terminally ill with metastasis and secondary cancers
- Also re-admitted patients were not assessed a second time.
Recruitment
All consecutive, mentally alert and ambulatory patients with cancer admitted as inpatients and outpatients at a palliative care unit of a Malaysian government hospital and a non-governmental hospice facility between January and April 2005.
Design
Cross-sectional.
Statistical Analysis
SPSS version 15.0 was used for all statistical analyses:
- Pearson's correlation to determine the relationship between PG-SGA scores and the objective nutritional variables
- One-way ANOVA test was performed for differences in objective nutritional indices among the three categories of PG-SGA
- Bonferroni post-hoc multiple comparison test was applied to further investigate significant differences between PG-SGA ratings
- Effect size was manually calculated to examine the magnitude of difference and interpreted by Cohen's guidelines
- A statistical probability level of P<0.050 was considered significant.
Timing of Measurements
Nutritional status was assessed by two different methods
- Anthropometric measurements
- A scored PG-SGA tool.
Dependent Variables
- Anthropometrics: Weight, height, body mass index, mid-upper-arm muscle circumference, triceps skinfold thickness and percentage of change in body weight within one month and six months
- Patient-Generated Subjective Global Assessment Score: Scoring range from zero to four; after assessment was complete a nutritional staging was given of (a) well nourished, (b) moderately malnourished or (c) severely malnourished.
- Initial N: 58 patients (29 male, 29 female)
- Attrition (final N): 58
- Age: 20 years to 74 years of age (mean, 58.4±13.1 years)
- Ethnicity: 64.8% Chinese; 24.1% Malay; 10.3% Indian; 1.7% others.
Other Relevant Demographics
- 74% of these patients were actively undergoing surgery, radiotherapy, chemotherapy or other alternative traditional treatments
- 67% of patients were prescribed with opioid analgesic drugs, morphine and other pain-killer medications
- 62.1% had Stage Four cancer; 24.1% had Stage Three cancer; 8.6% had Stage Two cancer; 5.2% had Stage One cancer
- 31.0% of patients were "well nourished," 50.0% were "moderately malnourished" and 19.0% were "severely malnourished"
- Most frequent nutrition impact symptoms were pain (55.2%), xerostamia (44.8%), anorexia (36.2%) and constipation (31.0%)
- Majority of the patients (41.4%) have three to four nutrition impact symptoms at the same time.
Anthropometrics
- Height: 158.85±11.82cm
- Weight: 52.98±13.13kg
- Weight loss at one month: 3.09±4.78%
- Weight loss at six months: 7.49±8.52%
- BMI (kg/m2): 20.85±3.98
- Triceps skinfold thickness: 8.04±3.96mm
- Mid-upper-arm circumference: 24.38±4.56cm
- Mid-upper-arm muscle circumference: 217.53±37.27mm
Location
Palliative care unit of a Malaysian government hospital and a non-governmental hospice facility.
Key Findings
- A statistically-significant difference at the P<0.050 level in anthropometric measures for the three PG-SGA stages
- Both mid-upper arm circumference and triceps skinfold thickness showed a moderate negative correlation between these two and PG-SGA score variables (R=-0.32, N=58, P<0.050), with low reading of anthropometric measures associated with higher scores of PG-SGA
- Anorexia is moderately correlated with problems of chewing and swallowing
- Nausea has a moderate correlation with vomiting and dysgeusia; xerostamia with mouth sores and early satiety; dysnomia with dysgeusia.
- The percentage of malnutrition in this study ranged between 31.0% and 69.0%
- There is still no consensus on which is the most appropriate to be applied in a specific palliative care setting. Weight loss was found to be a dominant characteristic of patients with poor nutritional status.
- Continuous weight loss has been shown to be a good predictor of negative complications and as part of the classical causes of cachexia
- A majority of patients with advanced cancer had normal-to-high BMI values
- Most of the patients with cancer appear to die with normal BMI status, despite significant weight loss
- This study does not provide a proper validation of the tool, but the initial findings showed that the scored PG-SGA is an undoubtedly convenient choice of nutritional status evaluation, as it was significantly correlated with anthropometric measurements
- This study suggests that the tool is practical, especially in busy palliative care units and often with fewer human resources
- A few anthropometric nutritional values, such as triceps skinfold thickness, weight loss in one or six months and BMI were not significantly different across the PG-SGA stages
- A limitation was the relatively small sample size and exclusion of objective biochemical parameters, such as inflammatory activity biomarkers (serum pre-albumin and high-sensitivity C-reactive protein), restricted a more comprehensive evaluation of the methods used and further understanding of the etiology of malnutrition in these patients.
University/Hospital: | Wyeth (Malaysia)Sdn Bhd and Stream-Line Industries Sdn Bhd |
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | N/A | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | N/A | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | N/A | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | Yes | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
2.2. | Were criteria applied equally to all study groups? | Yes | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | Yes | |
3. | Were study groups comparable? | Yes | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | N/A | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | Yes | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | N/A | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | Yes | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | Yes | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
4. | Was method of handling withdrawals described? | Yes | |
4.1. | Were follow-up methods described and the same for all groups? | Yes | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | Yes | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | Yes | |
4.4. | Were reasons for withdrawals similar across groups? | Yes | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | N/A | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | N/A | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | No | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | N/A | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | N/A | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | N/A | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | Yes | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | N/A | |
6.6. | Were extra or unplanned treatments described? | No | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | Yes | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | Yes | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | N/A | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | Yes | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |